A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Last month, Pfizer announced a $6 million agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, an additional bispecific antibody targeting PD-1 and VEGF pathways. According to ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The acquisition includes STC-004, a Phase II-ready Nav1.8 sodium channel inhibitor with the potential to be a next-generation, non-addictive pain therapy. Under the terms of the deal, SiteOne ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...